{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:22:41Z","timestamp":1791256961664,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T00:00:00Z","timestamp":1298332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00277-011-1175-6","type":"journal-article","created":{"date-parts":[[2011,2,21]],"date-time":"2011-02-21T11:47:31Z","timestamp":1298288851000},"page":"917-931","source":"Crossref","is-referenced-by-count":19,"title":["Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells"],"prefix":"10.1007","volume":"90","author":[{"given":"Ai-Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Xiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,22]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425\u2013479","journal-title":"Annu Rev Biochem"},{"key":"1175_CR2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrm1049","volume":"4","author":"M Muratani","year":"2003","unstructured":"Muratani M, Tansey WP (2003) How the ubiquitin\u2013proteasome system controls transcription. Nat Rev Mol Cell Biol 4:192\u2013201","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1175_CR3","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1053\/j.seminoncol.2009.02.001","volume":"36","author":"KC Anderson","year":"2009","unstructured":"Anderson KC (2009) Proteasome inhibitors in multiple myeloma. Semin Oncol 36:S20\u2013S26","journal-title":"Semin Oncol"},{"key":"1175_CR4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","volume":"18","author":"J Adams","year":"2000","unstructured":"Adams J, Palombella VJ, Elliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18:109\u2013121","journal-title":"Invest New Drugs"},{"key":"1175_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/138920106779116865","volume":"7","author":"AM Roccaro","year":"2006","unstructured":"Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC (2006) Bortezomib as an antitumor agent. Curr Pharm Biotechnol 7:441\u2013448","journal-title":"Curr Pharm Biotechnol"},{"key":"1175_CR6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1367-5931(02)00343-5","volume":"6","author":"J Adams","year":"2002","unstructured":"Adams J (2002) Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6:493\u2013500","journal-title":"Curr Opin Chem Biol"},{"key":"1175_CR7","first-page":"4996","volume":"62","author":"R LeBlanc","year":"2002","unstructured":"LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996\u20135000","journal-title":"Cancer Res"},{"key":"1175_CR8","first-page":"853","volume":"88","author":"S Gatto","year":"2003","unstructured":"Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88:853\u2013863","journal-title":"Haematologica"},{"key":"1175_CR9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.leukres.2003.12.010","volume":"28","author":"TW Kelley","year":"2004","unstructured":"Kelley TW, Alkan S, Srkalovic G, Hsi ED (2004) Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 28:845\u2013850","journal-title":"Leuk Res"},{"key":"1175_CR10","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-03-0494","volume":"10","author":"B Zheng","year":"2004","unstructured":"Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207\u20133215","journal-title":"Clin Cancer Res"},{"key":"1175_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.11666","volume":"93","author":"E Colado","year":"2008","unstructured":"Colado E, Alvarez-Fernandez S, Maiso P, Martin-Sanchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF (2008) The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 93:57\u201366","journal-title":"Haematologica"},{"key":"1175_CR12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","volume":"136","author":"C Stapnes","year":"2007","unstructured":"Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136:814\u2013828","journal-title":"Br J Haematol"},{"key":"1175_CR13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.leukres.2006.05.018","volume":"31","author":"E Terpos","year":"2007","unstructured":"Terpos E, Verrou E, Banti A, Kaloutsi V, Lazaridou A, Zervas K (2007) Bortezomib is an effective agent for MDS\/MPD syndrome with 5q-anomaly and thrombocytosis. Leuk Res 31:559\u2013562","journal-title":"Leuk Res"},{"key":"1175_CR14","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101:4055\u20134062","journal-title":"Blood"},{"key":"1175_CR15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI200111537","volume":"108","author":"LZ He","year":"2001","unstructured":"He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321\u20131330","journal-title":"J Clin Invest"},{"key":"1175_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","volume":"13","author":"PA Marks","year":"2001","unstructured":"Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477\u2013483","journal-title":"Curr Opin Oncol"},{"key":"1175_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2008.03.002","volume":"68","author":"C Gridelli","year":"2008","unstructured":"Gridelli C, Rossi A, Maione P (2008) The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 68:29\u201336","journal-title":"Crit Rev Oncol Hematol"},{"key":"1175_CR18","doi-asserted-by":"crossref","first-page":"44641","DOI":"10.1074\/jbc.M105170200","volume":"276","author":"L Yin","year":"2001","unstructured":"Yin L, Laevsky G, Giardina C (2001) Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 276:44641\u201344646","journal-title":"J Biol Chem"},{"key":"1175_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","volume":"80","author":"U Heider","year":"2008","unstructured":"Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80:133\u2013142","journal-title":"Eur J Haematol"},{"key":"1175_CR20","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","volume":"10","author":"XY Pei","year":"2004","unstructured":"Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839\u20133852","journal-title":"Clin Cancer Res"},{"key":"1175_CR21","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","volume":"102","author":"C Yu","year":"2003","unstructured":"Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571. Blood 102:3765\u20133774","journal-title":"Blood"},{"key":"1175_CR22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","volume":"23","author":"QL Zhang","year":"2009","unstructured":"Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL (2009) The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia 23:1507\u20131514","journal-title":"Leukemia"},{"key":"1175_CR23","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","volume":"15","author":"A Badros","year":"2009","unstructured":"Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15:5250\u20135257","journal-title":"Clin Cancer Res"},{"key":"1175_CR24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0145-2126(01)00151-5","volume":"26","author":"R Kawagoe","year":"2002","unstructured":"Kawagoe R, Kawagoe H, Sano K (2002) Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26:495\u2013502","journal-title":"Leuk Res"},{"key":"1175_CR25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.leukres.2007.03.012","volume":"31","author":"YC Cheng","year":"2007","unstructured":"Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE (2007) Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 31:1403\u20131411","journal-title":"Leuk Res"},{"key":"1175_CR26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2119\/molmed.2010.00062","volume":"17","author":"IV Ulasov","year":"2010","unstructured":"Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS (2010) Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 17:103\u2013112","journal-title":"Mol Med"},{"key":"1175_CR27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.21785","volume":"66","author":"Z Metting","year":"2009","unstructured":"Metting Z, Rodiger LA, Stewart RE, Oudkerk M, De Keyser J, van der Naalt J (2009) Perfusion computed tomography in the acute phase of mild head injury: regional dysfunction and prognostic value. Ann Neurol 66:809\u2013816","journal-title":"Ann Neurol"},{"key":"1175_CR28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.21926","volume":"67","author":"LE Glover","year":"2010","unstructured":"Glover LE, Newton K, Krishnan G, Bronson R, Boyle A, Krivickas LS, Brown RH Jr (2010) Dysferlin overexpression in skeletal muscle produces a progressive myopathy. Ann Neurol 67:384\u2013393","journal-title":"Ann Neurol"},{"key":"1175_CR29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ana.22034","volume":"68","author":"C Perier","year":"2010","unstructured":"Perier C, Bove J, Dehay B, Jackson-Lewis V, Rabinovitch PS, Przedborski S, Vila M (2010) Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol 68:184\u2013192","journal-title":"Ann Neurol"},{"key":"1175_CR30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.21644","volume":"65","author":"S Arbogast","year":"2009","unstructured":"Arbogast S, Beuvin M, Fraysse B, Zhou H, Muntoni F, Ferreiro A (2009) Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment. Ann Neurol 65:677\u2013686","journal-title":"Ann Neurol"},{"key":"1175_CR31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2119\/molmed.2009.00168","volume":"16","author":"AA Kazi","year":"2010","unstructured":"Kazi AA, Lang CH (2010) PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts. Mol Med 16:359\u2013371","journal-title":"Mol Med"},{"key":"1175_CR32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ana.21919","volume":"67","author":"Y Fan","year":"2010","unstructured":"Fan Y, Shen F, Frenzel T, Zhu W, Ye J, Liu J, Chen Y, Su H, Young WL, Yang GY (2010) Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol 67:488\u2013497","journal-title":"Ann Neurol"},{"key":"1175_CR33","doi-asserted-by":"crossref","first-page":"9695","DOI":"10.1128\/MCB.24.22.9695-9704.2004","volume":"24","author":"A Fribley","year":"2004","unstructured":"Fribley A, Zeng Q, Wang CY (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695\u20139704","journal-title":"Mol Cell Biol"},{"key":"1175_CR34","doi-asserted-by":"crossref","first-page":"31674","DOI":"10.1074\/jbc.M104309200","volume":"276","author":"PX Yuan","year":"2001","unstructured":"Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276:31674\u201331683","journal-title":"J Biol Chem"},{"key":"1175_CR35","first-page":"248","volume":"91","author":"M Kaiser","year":"2006","unstructured":"Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91:248\u2013251","journal-title":"Haematologica"},{"key":"1175_CR36","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","volume":"110","author":"A Kuendgen","year":"2007","unstructured":"Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110:943\u2013954","journal-title":"Cancer"},{"key":"1175_CR37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0006-2952(98)00227-5","volume":"57","author":"T Jabs","year":"1999","unstructured":"Jabs T (1999) Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol 57:231\u2013245","journal-title":"Biochem Pharmacol"},{"key":"1175_CR38","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/sj.leu.2405079","volume":"22","author":"C Nishioka","year":"2008","unstructured":"Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A (2008) Inhibition of MEK\/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22:1449\u20131452","journal-title":"Leukemia"},{"key":"1175_CR39","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2403868","volume":"19","author":"C Yu","year":"2005","unstructured":"Yu C, Dasmahapatra G, Dent P, Grant S (2005) Synergistic interactions between MEK1\/2 and histone deacetylase inhibitors in BCR\/ABL+ human leukemia cells. Leukemia 19:1579\u20131589","journal-title":"Leukemia"},{"key":"1175_CR40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","volume":"107","author":"T Braun","year":"2006","unstructured":"Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F, Kiladjian JJ, Ribrag V, Fenaux P, Kroemer G (2006) NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107:1156\u20131165","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1175-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1175-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T10:09:35Z","timestamp":1712225375000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1175-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,22]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1175-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,22]]}}}